These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 19814923)
1. [Is there a future for medical treatment of obesity?]. Richelsen B Ugeskr Laeger; 2009 Oct; 171(41):2973. PubMed ID: 19814923 [No Abstract] [Full Text] [Related]
3. [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]. Nielsen AL; Larsen TM; Madsbad S; Breum L; Jensen TJ; Kroustrup JP; Astrup A Ugeskr Laeger; 2009 Oct; 171(41):2974-7. PubMed ID: 19824222 [TBL] [Abstract][Full Text] [Related]
4. Is new hope on the horizon for obesity? Bray GA Lancet; 2008 Nov; 372(9653):1859-1860. PubMed ID: 19041787 [No Abstract] [Full Text] [Related]
5. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Bello NT; Zahner MR Curr Opin Investig Drugs; 2009 Oct; 10(10):1105-16. PubMed ID: 19777399 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficiency and safety of pharmacological approaches to the management of obesity. Hainer V Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S349-54. PubMed ID: 21525481 [No Abstract] [Full Text] [Related]
7. The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. Tizzano JP; Stribling DS; Perez-Tilve D; Strack A; Frassetto A; Chen RZ; Fong TM; Shearman L; Krieter PA; Tschöp MH; Skolnick P; Basile AS J Pharmacol Exp Ther; 2008 Mar; 324(3):1111-26. PubMed ID: 18089843 [TBL] [Abstract][Full Text] [Related]
8. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Gadde KM; Allison DB Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206 [No Abstract] [Full Text] [Related]
9. The advances on the knowledge base of obesity and future therapeutic directions. Vettor R; Pagano C; Federspil G Eat Weight Disord; 2001 Sep; 6(3 Suppl):40-3. PubMed ID: 11706508 [No Abstract] [Full Text] [Related]
10. [Effectiveness and risks of medicamentous treatment of obesity]. Pavel J Cas Lek Cesk; 2010; 149(12):605. PubMed ID: 21387588 [No Abstract] [Full Text] [Related]
11. First do no harm with anti-obesity and other drugs. Toussaint B BMJ; 2013 May; 346():f3026. PubMed ID: 23716495 [No Abstract] [Full Text] [Related]
13. European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes. Jordan J; Schlaich M; Redon J; Narkiewicz K; Luft FC; Grassi G; Dixon J; Lambert G; Engeli S; ; J Hypertens; 2011 Feb; 29(2):189-93. PubMed ID: 21178784 [No Abstract] [Full Text] [Related]
14. Another type of intervention: treating obesity with medication. Greenway F J Am Diet Assoc; 2005 Jun; 105(6):895-8. PubMed ID: 15942538 [No Abstract] [Full Text] [Related]
15. Pharmaceutical treatment of obesity. Blackburn GL; Miller D; Chan S Nurs Clin North Am; 1997 Dec; 32(4):831-48. PubMed ID: 9386228 [TBL] [Abstract][Full Text] [Related]
16. Anti-obesity drugs: to be or not to be? Dvorak RV; Sharma AM; Astrup A Obes Rev; 2010 Dec; 11(12):833-4. PubMed ID: 21054758 [No Abstract] [Full Text] [Related]
17. [Long way towards a successful drug treatment of obesity]. Rössner S Lakartidningen; 2011 Dec 7-13; 108(49):2578-80. PubMed ID: 22468394 [No Abstract] [Full Text] [Related]
18. Dietary supplements for weight loss: challenges in evaluation. Allison DB Obes Rev; 2005 May; 6(2):89-92. PubMed ID: 15836458 [No Abstract] [Full Text] [Related]